/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. The Top Line
  2.  What did we learn from Big Pharma’s Q2 results?
 What did we learn from Big Pharma’s Q2 results?

 What did we learn from Big Pharma’s Q2 results?

The Top Line · Aug 21, 2026

Big Pharma's Q2 shows strong sales amid patent cliff threats. Firms detail AI use, new CEOs pivot strategy, & the obesity race intensifies.

Roche CEO Details a Practical Three-Tiered Strategy for Enterprise AI Adoption

Roche's CEO, Thomas Scheinke, demystifies AI implementation by breaking it down into three distinct levels: 'everyday AI' for workforce productivity, AI for 'core processes' like regulatory filings, and 'big ideas' for disruptive R&D approaches. This structured framework provides a clear roadmap for integrating AI across a large organization, moving beyond hype to practical application.

 What did we learn from Big Pharma’s Q2 results? thumbnail

 What did we learn from Big Pharma’s Q2 results?

The Top Line·3 months ago

Novo Nordisk Flips the Script on Eli Lilly with Dominant Oral Obesity Drug Launch

After lagging Eli Lilly in the injectable obesity drug market, Novo Nordisk has reversed the dynamic by successfully launching its oral version, Wagovi pill, first. This head start has given Novo a substantial lead in sales and prescriptions in the new oral segment, demonstrating how a shift in drug delivery format can completely reset a competitive landscape.

 What did we learn from Big Pharma’s Q2 results? thumbnail

 What did we learn from Big Pharma’s Q2 results?

The Top Line·3 months ago

Sarepta CEO Highlights Revenue Lag in Gene Therapy Commercialization

Sarepta's new CEO revealed a significant lag between positive commercial indicators (increased patient enrollment) and actual revenue for its gene therapy, Elevidys. Revenue improvements won't be seen until 2027, highlighting a crucial challenge in the gene therapy space where the complex patient journey from enrollment to infusion creates a long delay in financial returns for investors.

 What did we learn from Big Pharma’s Q2 results? thumbnail

 What did we learn from Big Pharma’s Q2 results?

The Top Line·3 months ago

AstraZeneca CEO Targets AI at Costly Phase 3 Trials, Not Just Early Discovery

AstraZeneca's CEO, Pascal Soriot, is focusing AI on optimizing expensive late-stage clinical trials to improve success rates. This strategic shift from the common focus on early-stage discovery targets the area of greatest expense in drug development. He also downplayed AI's impact on jobs, calling the idea a 'fake story' and aiming to make people 'faster and smarter.'

 What did we learn from Big Pharma’s Q2 results? thumbnail

 What did we learn from Big Pharma’s Q2 results?

The Top Line·3 months ago

Big Pharma Achieves Strong Growth Despite Patent Cliffs and Pricing Pressures

Despite facing existential threats like patent expirations, the Inflation Reduction Act, and other policy pressures, the pharmaceutical industry shows remarkable financial health. In Q2, nine of the top 25 drugmakers posted double-digit revenue growth, demonstrating that innovation and strong commercial franchises are currently outweighing significant market headwinds.

 What did we learn from Big Pharma’s Q2 results? thumbnail

 What did we learn from Big Pharma’s Q2 results?

The Top Line·3 months ago

Sanofi's New CEO Signals a Major Cull of Its Late-Stage Drug Pipeline

New Sanofi CEO Belain Garijo is signaling a fundamental R&D overhaul focused on fixing the company's struggling pipeline. Her comments about deeply reviewing the 'late stage portfolio' and not having a 'target number of products to discontinue' suggest a ruthless culling process is underway to de-risk the pipeline and find a true successor to the blockbuster Dupixent.

 What did we learn from Big Pharma’s Q2 results? thumbnail

 What did we learn from Big Pharma’s Q2 results?

The Top Line·3 months ago

BridgeBio's Drug Nears Blockbuster Status as Key Competitors' Trials Fail

BridgeBio's drug Atrubi is on a path to blockbuster sales not just due to its own performance, but because of strategic failures by its competitors. The failure of a rival drug from AstraZeneca and Ionis is reshaping the market, leading BridgeBio's CEO to predict it will become a 'stabilizer-first market,' cementing his drug's dominant position.

 What did we learn from Big Pharma’s Q2 results? thumbnail

 What did we learn from Big Pharma’s Q2 results?

The Top Line·3 months ago